CL2016002721A1 - Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina - Google Patents

Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina

Info

Publication number
CL2016002721A1
CL2016002721A1 CL2016002721A CL2016002721A CL2016002721A1 CL 2016002721 A1 CL2016002721 A1 CL 2016002721A1 CL 2016002721 A CL2016002721 A CL 2016002721A CL 2016002721 A CL2016002721 A CL 2016002721A CL 2016002721 A1 CL2016002721 A1 CL 2016002721A1
Authority
CL
Chile
Prior art keywords
bis
hexanediyl
dioxo
prodrug
proline
Prior art date
Application number
CL2016002721A
Other languages
English (en)
Inventor
Alexis Denis
Olivier Mirguet
Jérôme Toum
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2016002721A1 publication Critical patent/CL2016002721A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>EL COMPUESTO 1,1-adipoilois(pirrolidina-2- carboxilato) de (2R2R)-Bis(((((tetrahidro-2H-piran-4-iI)oxi)carbonil)oxi)metilo; SU FORMA CRISTALINA; COMPOSICION FARMACEUTICA; KIT; Y SU USO PARA EL TRATAMIENTO DE AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER, ENTRE OTRAS.</p>
CL2016002721A 2014-04-29 2016-10-26 Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina CL2016002721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound

Publications (1)

Publication Number Publication Date
CL2016002721A1 true CL2016002721A1 (es) 2017-01-20

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002721A CL2016002721A1 (es) 2014-04-29 2016-10-26 Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina

Country Status (26)

Country Link
US (3) US9701668B2 (es)
EP (1) EP3137457B1 (es)
JP (1) JP6445046B2 (es)
KR (1) KR20160145617A (es)
CN (1) CN106459016B (es)
AR (1) AR100204A1 (es)
AU (1) AU2015252184B2 (es)
BR (1) BR112016025129A2 (es)
CA (1) CA2947060C (es)
CL (1) CL2016002721A1 (es)
CR (1) CR20160508A (es)
DO (1) DOP2016000292A (es)
EA (1) EA032129B1 (es)
ES (1) ES2731253T3 (es)
GB (1) GB201407506D0 (es)
IL (2) IL248249A0 (es)
MA (1) MA39406B1 (es)
MX (1) MX2016014246A (es)
MY (1) MY191088A (es)
PE (1) PE20161558A1 (es)
PH (1) PH12016502006A1 (es)
SG (1) SG11201608371RA (es)
TW (1) TWI676624B (es)
UA (1) UA119871C2 (es)
UY (1) UY36098A (es)
WO (1) WO2015165833A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2182203T3 (es) 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
JP2006526612A (ja) 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
CA2604206A1 (en) 2005-04-12 2006-10-19 Meiji Seika Kaisha, Ltd. 2-thioethenyl substituted carbapenem derivatives
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
BR112016025129A2 (pt) 2017-08-15
CN106459016A (zh) 2017-02-22
KR20160145617A (ko) 2016-12-20
WO2015165833A1 (en) 2015-11-05
AU2015252184A1 (en) 2016-10-27
AU2015252184B2 (en) 2017-11-02
EA032129B1 (ru) 2019-04-30
CN106459016B (zh) 2019-11-01
TW201625598A (zh) 2016-07-16
MY191088A (en) 2022-05-30
EA201692185A1 (ru) 2017-06-30
MA39406A1 (fr) 2017-07-31
US9873686B2 (en) 2018-01-23
SG11201608371RA (en) 2016-11-29
ES2731253T3 (es) 2019-11-14
US10597385B2 (en) 2020-03-24
EP3137457B1 (en) 2019-04-17
TWI676624B (zh) 2019-11-11
JP2017514829A (ja) 2017-06-08
AR100204A1 (es) 2016-09-21
IL248249A0 (en) 2016-11-30
JP6445046B2 (ja) 2018-12-26
IL279120A (en) 2021-01-31
US20180099955A1 (en) 2018-04-12
CR20160508A (es) 2017-03-10
PH12016502006B1 (en) 2016-12-19
PE20161558A1 (es) 2017-01-06
UY36098A (es) 2015-11-30
DOP2016000292A (es) 2017-11-15
PH12016502006A1 (en) 2016-12-19
UA119871C2 (uk) 2019-08-27
GB201407506D0 (en) 2014-06-11
CA2947060C (en) 2023-09-26
US20170267665A1 (en) 2017-09-21
EP3137457A1 (en) 2017-03-08
US9701668B2 (en) 2017-07-11
MA39406B1 (fr) 2018-04-30
US20160075694A1 (en) 2016-03-17
MX2016014246A (es) 2017-02-06
CA2947060A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PH12016501813A1 (en) 1,3-benzodioxole derivative
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CL2015001358A1 (es) Potenciadores del cftr deuterados
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CR20170315A (es) Inhibridores bace 1 selectivos
GT201300254A (es) Triazolopiridinas
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
AR093705A1 (es) Depsipeptido y sus usos
CL2014000447A1 (es) Compuestos derivados de piridina y pirimidina sustituidos, mediadores de quinurenina-3-monooxigenasa; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una patologia neurodegenerativa, tal como la enfermedad de huntington.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CR20160016A (es) Pirazolpiridinas sustituidas
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2016002721A1 (es) Un profármaco de 1,1&#39;-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112019023322A2 (pt) Sanfetrona ou um sal ou éster do mesmo para utilização no tratamento de infecção micobacteriana
WO2016020408A3 (en) Compounds for preventing ototoxicity
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel